Oragenics Bilan de santé

Santé financière contrôle des critères 6/6

Oragenics possède un total de capitaux propres de $1.3M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $2.7M et de $1.4M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$1.35m
Fonds propres	US$1.33m
Total du passif	US$1.38m
Total des actifs	US$2.71m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de OGEN ( $1.6M ) dépassent ses passifs à court terme ( $1.4M ).

Passif à long terme: OGEN n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: OGEN est sans dette.

Réduire la dette: OGEN n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 0.05%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: OGEN dispose d'une piste de trésorerie suffisante pour 2 mois sur la base du dernier rapport flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: OGEN devrait disposer d'une marge de trésorerie suffisante pour 2 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Oragenics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Recent updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

New major risk - Financial position

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines